Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Hookipa Biotech
Hookipa Biotech
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Drug Delivery
Hookipa achieves $10 million towards immunotherapy for KRAS-mutated cancers
“We’re excited to advance the HB-700 program, our third in oncology, and we’re eager to explore the potential of our technology in addressing another unmet need in cancer.”
Regulatory
FDA accepts HOOKIPA’s IND application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase I/II trial to commence by early 2023
Research & Development
Hookipa and Gilead amend HIV immunotherapy agreement
Under the original agreement, Gilead would assume rights for further development following a joint research phase
Research & Development
Hookipa announces clinical collaboration with Merck USA
The collaboration will evaluate the combination of Hookipa’s arenaviral immunotherapeutic, and Merck’s Keytruda as treatment for patients with advanced head and neck squamous cell carcinoma
Research & Development
Hookipa Gilead collaboration reaches major milestones
The license agreement to focus on HBV and HIV has now delivered 24 research-grade vectors
Recruitment
Dr Jan van de Winkel joins Hookipa as Chairman of its Board of Directors
Reinhard Kandera appointed CFO of Hookipa Biotech
Subscribe now